CNW/ - Health Canada has granted a Notice of Compliance (NOC) for Saphnelo® (anifrolumab injection) for subcutaneous self-administration via a ...
AstraZeneca has reported positive results from the efzimfotase alfa Phase III clinical trial programme for hypophosphatasia ...
After another swing and a miss for AstraZeneca's Fasenra in chronic obstructive pulmonary disease (COPD), the company is pivoting to other options in its portfolio that might have potential to treat ...
AstraZeneca Plc AZN released topline data from the Phase 3 program for efzimfotase alfa (ALXN1850) in the broad hypophosphatasia (HPP) patient population. HPP is a rare, inherited metabolic disorder ...
A potential treatment developed by AstraZeneca for hypophosphatasia has showed positive results in phase III trials, the ...
The experimental therapy tozorakimab from AstraZeneca was superior to a placebo at reducing the rate of moderate to severe exacerbations, or sudden episodes of symptom worsening, in adults with ...
The U.S. Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in combination with pertuzumab for patients with a ...
The US Food and Drug Administration turned down a self-administered version of AstraZeneca Plc’s lupus medicine, but the UK drugmaker said it’s still working with regulators to advance the request.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results